Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats
Authors:
- Jonas PetersenJPJonas Petersen
- Christoffer MerrildCMChristoffer Merrild
- Stephanie Kjærulff HolmSHStephanie Kjærulff Holm
- Nigel KurganNKNigel Kurgan
- Shad HassanSHShad Hassan
- Cecilie Vad MathiesenCMCecilie Vad Mathiesen
- Stina BörchersSBStina Börchers
- Charlotte SvendsenCSCharlotte Svendsen
- Sergio D’ANnaSDSergio D’ANna
- Nicoline R. AndersenNANicoline R. Andersen
- Andreas M. FritzenAndreas M. Fritzen
- 15 September 2026
- journal article
- letter
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2069-2083
Abstract
Peptide multi-receptor agonists have advanced obesity treatment, yet challenges remain in achieving maximal weight loss and metabolic control, especially in patients with obesity and type 2 diabetes. Here we demonstrate enhanced metabolic benefits of a combination therapy with retatrutide, a unimolecular GLP-1R/GIPR/GCGR tri-agonist, and cagrilintide, an AMLNR/CALCR co-agonist, in diet-induced obese male rats. Daily co-administration produces dose-dependent reductions in body weight and food intake that exceed both equimolar monotherapies and matched-dose comparator combinations incorporating semaglutide or tirzepatide. The combination therapy also improves circulating markers of metabolic health, including cholesterol, triglycerides and insulin levels. Pair-feeding and weight-matching studies reveal that the enhanced weight loss cannot be explained by reduced food intake alone and enable discrimination between weight-loss-dependent and drug-specific molecular responses. Plasma proteomic profiling highlights enrichment of bioenergetic processes with the combination therapy, whereas brain transcriptomic profiling identifies convergent central neuronal programmes linked to energy balance regulation. Collectively, our preclinical findings support five-receptor polypharmacology as a strategy for efficaciously lowering body weight and provide guidance for the design of next-generation unimolecular multi-receptor agonists.Keywords
Funding Information
- Novo Nordisk Fonden
This publication has 58 references indexed in Scilit:
- NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granulesNature Genetics, 2011
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression dataBioinformatics, 2009
- WGCNA: an R package for weighted correlation network analysisBMC Bioinformatics, 2008
- Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cellsProceedings of the National Academy of Sciences, 2007
- Targeted Deletion of the Vgf Gene Indicates that the Encoded Secretory Peptide Precursor Plays a Novel Role in the Regulation of Energy BalanceNeuron, 1999
- Chromogranin B (secretogranin I), a neuroendocrine‐regulated secretory protein, is sorted to exocrine secretory granules in transgenic miceThe EMBO Journal, 1998
- RGS10 is a selective activator of Gαi GTPase activityNature, 1996
- Amylin binding in rat renal cortex, stimulation of adenylyl cyclase, and activation of plasma reninAmerican Journal of Physiology-Renal Physiology, 1996
- Glucagon receptors along the nephron: [125I]glucagon binding in rat tubulesPflügers Archiv - European Journal of Physiology, 1985
- A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUESJournal of Biological Chemistry, 1957